cremophor el has been researched along with tanespimycin in 2 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 1 (50.00) | 29.6817 |
| 2010's | 1 (50.00) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Davies, NM; Forrest, ML; Kwon, GS; Xiong, MP; Yáñez, JA | 1 |
| Berman, D; Burris, HA; Jones, S; Murthy, B | 1 |
1 trial(s) available for cremophor el and tanespimycin
| Article | Year |
|---|---|
Tanespimycin pharmacokinetics: a randomized dose-escalation crossover phase 1 study of two formulations.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Agents; Benzoquinones; Cross-Over Studies; Excipients; Female; Glycerol; HSP90 Heat-Shock Proteins; Humans; Lactams, Macrocyclic; Male; Middle Aged; Suspensions | 2011 |
1 other study(ies) available for cremophor el and tanespimycin
| Article | Year |
|---|---|
A cremophor-free formulation for tanespimycin (17-AAG) using PEO-b-PDLLA micelles: characterization and pharmacokinetics in rats.
Topics: Animals; Benzoquinones; Cell Line, Tumor; Cell Survival; Dioxanes; Drug Carriers; Glycerol; Humans; Lactams, Macrocyclic; Male; Micelles; Nanoparticles; Polyethylene Glycols; Rats; Rats, Sprague-Dawley; Solubility; Tissue Distribution | 2009 |